ArborGen Holdings Limited Analysis

Overview

The shares were listed in March 2001 as part of a recapitalisation of Fletcher Challenge Forests, and to acquire certain assets from Fletcher Challenge Energy. These included 594,000 ordinary shares in NASDAQ listed Capstone Turbine Corporation and the Challenge retail service station network in NZ. All of these interests were later sold. Remaining assets were acquired from Fletcher Challenge Forests following its recapitalisation. These included a 50% interest in FTSA, an Argentinean joint venture and interests in established biotechnology businesses - ArborGen, Trees & Technology and listed Genesis Research & Development. The company also held a 19.9% stake in Fletcher Challenge Forests.

In March 2004 RBC and Carter Holt Harvey agreed to merge their forestry biotechnology and propagation operations into a new venture - Horizon2. In June 2004 it acquired 50.01% of listed wood products company Tenon.

Performance

The following information was extracted from ArborGen Holdings Limited's full year results, released on 29 May 2026:

FY26 Summary (in USD, comparatives to FY25):

• Group revenue of $68.2m the highest in five years, driven by increasing average sales prices across both markets.

• Adjusted US GAAP EBITDA1 up 31% to $11.5m.

• Continued growth momentum in Brazil; sales up 14% in local currency, provided 44% of total revenue.

• US sales revenue in line with prior year; business repositioned for structural industry reset.

• Clear strategy being executed with discipline - focus on continued growth momentum in Brazil; higher value sales mix in the US South; and continued strengthening of the operational platform.

ArborGen has delivered its highest revenue result in the past five years, alongside a strong uplift in earnings. The result was driven by strong growth momentum in Brazil, a focus on added value products in both of ArborGen’s markets and increased commercial discipline across the business.

Group revenue increased 8% year-on-year (YOY) to $68.2m. Excluding one-off, non-recurring items of $1.0m, Adjusted US GAAP EBITDA was $11.5m, representing a 31% increase on FY25. The company reported a net loss after tax of $(7.5)m, a material improvement on the prior year.

The Board remains firmly focused on cash generation, reducing debt and delivering further cost initiatives, including rightsizing the business to better reflect ongoing structural changes in the US market, and investment into the Brazil business to support continued growth.

Cash and cash equivalents were $2.2m as at 31 March 2026, with net debt of $25.2m reflecting several years of strategic investment across the business. Certain bank facilities were renewed during the year, providing more advantageous rates and terms. ArborGen’s Ridgeville building remains on the market for sale and is supported by a strong commercial tenant. Any future sale proceeds are intended to further reduce debt.

CEO Justin Birch said: “While market conditions in the US South remain challenging, our deliberate strategy over the past five years to diversify market concentration and expand our presence in Brazil is delivering. We are seeing customers increasingly recognise our value proposition, with growing demand for our advanced genetics seedlings, protected clones and containerised seedlings.

“Operationally, we are building a stronger platform for long-term growth by optimising our asset base, improving efficiency and productivity, and embedding a high-performance culture. We have invested in a new ERP system which went live in April 2026 and will further strengthen operational visibility and efficiency. We now have a leaner, faster operation that can scale as advanced genetics demand grows, without proportionally growing our cost base.

“The growing integration and collaboration between our regional business divisions continues to strengthen the Group, creating new opportunities for growth and further establishing us as an increasingly connected international business.

“We remain confident that our dual pathway strategy remains the right framework for long term value creation: accelerate adoption of higher-value advanced genetics, and build the operational infrastructure to supply those genetics reliably, at scale, everywhere we compete.